Tag Archives: DDMAC

Following Industry, OPDP Hopes to Eliminate Silos in Ad Review

The Office of Prescription Drug Promotion (OPDP) is reorganizing its two primary advertising review divisions – professional and consumer – in an attempt to stay in line with the silo-breaking, multi-channel promotional output pouring in from pharma. The line between physician marketing and consumer marketing has blurred as the facets of a brand campaign – […]
Posted in Advertising, compliance, E-Media, FDA, Legal, Marketing, Patient Communication, patient education, Regulatory, Sales, social media | Also tagged , , | Leave a comment

Genentech Runs Voluntary Corrective Ads for Boniva

Even though Roche-owned Genentech wasn’t required to run costly corrective advertisements following an FDA Untitled Letter on Boniva last January, the company has done so anyway.
Posted in Advertising, compliance, Corporate Responsibility, FDA, leadership, Legal, Marketing, Regulatory | Also tagged , , | Leave a comment

DIA: Social Media Guidelines are DDMAC’s "Highest Priority"

Tom Abrams, director of FDA’s Division (soon to be Office) of Drug Marketing, Advertising & Communications (DDMAC), said that publishing social media guidelines for industry is the division’s “highest priority,” and that the document will be “published as soon as it’s vetted.”
Posted in Advertising, E-Media, FDA, Marketing, Meetings, patient education, Regulatory, social media, Strategy, Technology | Also tagged , | 1 Comment

Bad Ad: One Year of Fear

FDA’s Bad Ad program, launched in May of 2010, resulted in some 328 reports of potentially untruthful or misleading promotion, a handful of Warning Letters, and several Untitled Letters. But the single most effective tool in the Bad Ad program’s toolkit, according to Arnie Friede, principal at Arnold I. Friede & Associates, and a former […]
Posted in Advertising, compliance, Corporate Responsibility, FDA, Legal, Marketing, Regulatory | Also tagged , , | Leave a comment

New FDA Campaign Targets Detailing, Trade Shows

In addition to sending out more warning letters and stepping up enforcement activity, the Food and Drug Administration wants health professionals to do more to police drug marketing and advertising. The agency’s “Bad Ad” program urges doctors and other health professionals to report any false or misleading ads or inappropriate marketing pitches. Depending on one’s […]
Posted in FDA, News, Regulatory | Also tagged , , , , , | Leave a comment
  • Categories

  • Meta